Heidi Hagen
CIK 1585084 · Interim CEO · last filed 2026-05-01
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$1.62M
Companies
3
Total Filings
25
Lifetime Open-Market Net
-$890.1K
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| VCEL | Director | 35,050 | $46.24 | $1.62M | -$931.9K | 18 | 2026-05-01 |
| Alaunos Therapeutics, Inc. (ZIOP) Delisted | Interim CEO | 145,889 | $0.87 | $126.3K | $41.8K | 4 | 2021-09-03 |
| Vericel Corp (ASTM) Delisted | Director | — | — | — | $0 | 1 | 2013-08-27 |
Recent Filings · Page 2 of 3
25 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2022-04-29 | VCEL | Mixed | +2,600 | $0 | EDGAR |
| 2021-09-03 | Alaunos Therapeutics, Inc. (ZIOP) Delisted | Buy (P) | +23,770 | $41.8K | EDGAR |
| 2021-05-20 | VCEL | Exer (M) | +6,750 | $34.9K | EDGAR |
| 2021-04-30 | VCEL | Mixed | +1,750 | $0 | EDGAR |
| 2021-03-08 | Alaunos Therapeutics, Inc. (ZIOP) Delisted | Grant (A) | +90,000 | $0 | EDGAR |
| 2020-05-01 | VCEL | Mixed | +1,750 | $0 | EDGAR |
| 2020-01-03 | Alaunos Therapeutics, Inc. (ZIOP) Delisted | Grant (A) | +31,780 | $0 | EDGAR |
| 2019-06-17 | Alaunos Therapeutics, Inc. (ZIOP) Delisted | Grant (A) | — | $0 | EDGAR |
| 2019-05-03 | VCEL | Grant (A) | — | $0 | EDGAR |
| 2018-05-03 | VCEL | Grant (A) | — | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.